Clinical features and NPM1 and FLT3 mutations in AML and RAEB-t patients at diagnosis
. | NPM1-mut/FLT3-ITDneg . | NPM1-mut/FLT3-ITDpos . | NPM1-wt/FLT3-ITDpos . | NPM1-wt/FLT3-ITDneg . |
|---|---|---|---|---|
| No. | 244 | 164 | 148 | 929 |
| Median BM blasts, % (range) | 67.3 (6-95)* | 75.5 (29.5-100)* | 73 (11-96) | 56 (0.5-98.5) |
| Median WBC count, × 109/L (range) | 26.3 (0.5-380)* | 50 (1.1-372)* | 36 (0.8-465) | 7.7 (0.3-450) |
| Median platelet count, × 109/L (range) | 68 (7-302)* | 56 (3-514) | 47 (5-372) | 46 (4-1430) |
| Median LDH level, U/mL (range) | 449 (27-4065)* | 544 (23-7250)* | 607 (16-7096) | 369 (4.5-5274) |
| Median age, y (range) | 60 (18-83) | 57.5 (19-81) | 54 (17-83) | 58 (15-87) |
| Female, % | 55.3 | 62.2 | 49.3 | 43.3 |
| De novo AML, no. (%) | 223 (91.4)* | 150 (91.5) | 129 (87.2) | 719 (77.4) |
| Prior MDS, no. (%) | 16 (6.6)* | 12 (7.3) | 12 (8.1) | 149 (16.0) |
| TAML, no. (%) | 2 (0.8)* | 2 (1.2) | 5 (3.4) | 46 (5.0) |
| FAB‡ | ||||
| M0, no. (%) | 0 (0)* | 2 (1.2) | 2 (1.4) | 57 (6.1) |
| M1, no. (%) | 50 (20.5) | 47 (28.7) | 43 (29.1) | 180 (19.4) |
| M2, no. (%) | 79 (32.4) | 50 (30.5) | 37 (25) | 290 (19.4) |
| M3, no. (%) | 0 (0)* | 0 (0) | 12 (8.1) | 43 (4.6) |
| M4, no. (%) | 37 (15.2) | 20 (12.2) | 27 (18.2) | 87 (9.4) |
| M4eo, no. (%) | 1 (0.4) | 0 (0) | 4 (2.7) | 66 (7.1) |
| M5a, no. (%) | 41 (16.8)† | 25 (15.2) | 11 (7.4) | 78 (8.4) |
| M5b, no. (%) | 21 (8.6)* | 14 (8.5) | 1 (0.7) | 14 (1.5) |
| M6, no. (%) | 2 (0.8)† | 0 (0) | 2 (1.4) | 46 (5.0) |
| M7, no. (%) | 0 (0) | 2 (1.2) | 0 (0) | 10 (1.1) |
| RAEB-t, no. (%) | 7 (2.9) | 1 (0.6) | 2 (1.4) | 37 (4.0) |
| RAEB1, no. (%) | 1 (0.4) | 0 (0) | 0 (0) | 5 (0.5) |
| RAEB2, no. (%) | 2 (0.8) | 0 (0) | 2 (1.4) | 10 (1.1) |
. | NPM1-mut/FLT3-ITDneg . | NPM1-mut/FLT3-ITDpos . | NPM1-wt/FLT3-ITDpos . | NPM1-wt/FLT3-ITDneg . |
|---|---|---|---|---|
| No. | 244 | 164 | 148 | 929 |
| Median BM blasts, % (range) | 67.3 (6-95)* | 75.5 (29.5-100)* | 73 (11-96) | 56 (0.5-98.5) |
| Median WBC count, × 109/L (range) | 26.3 (0.5-380)* | 50 (1.1-372)* | 36 (0.8-465) | 7.7 (0.3-450) |
| Median platelet count, × 109/L (range) | 68 (7-302)* | 56 (3-514) | 47 (5-372) | 46 (4-1430) |
| Median LDH level, U/mL (range) | 449 (27-4065)* | 544 (23-7250)* | 607 (16-7096) | 369 (4.5-5274) |
| Median age, y (range) | 60 (18-83) | 57.5 (19-81) | 54 (17-83) | 58 (15-87) |
| Female, % | 55.3 | 62.2 | 49.3 | 43.3 |
| De novo AML, no. (%) | 223 (91.4)* | 150 (91.5) | 129 (87.2) | 719 (77.4) |
| Prior MDS, no. (%) | 16 (6.6)* | 12 (7.3) | 12 (8.1) | 149 (16.0) |
| TAML, no. (%) | 2 (0.8)* | 2 (1.2) | 5 (3.4) | 46 (5.0) |
| FAB‡ | ||||
| M0, no. (%) | 0 (0)* | 2 (1.2) | 2 (1.4) | 57 (6.1) |
| M1, no. (%) | 50 (20.5) | 47 (28.7) | 43 (29.1) | 180 (19.4) |
| M2, no. (%) | 79 (32.4) | 50 (30.5) | 37 (25) | 290 (19.4) |
| M3, no. (%) | 0 (0)* | 0 (0) | 12 (8.1) | 43 (4.6) |
| M4, no. (%) | 37 (15.2) | 20 (12.2) | 27 (18.2) | 87 (9.4) |
| M4eo, no. (%) | 1 (0.4) | 0 (0) | 4 (2.7) | 66 (7.1) |
| M5a, no. (%) | 41 (16.8)† | 25 (15.2) | 11 (7.4) | 78 (8.4) |
| M5b, no. (%) | 21 (8.6)* | 14 (8.5) | 1 (0.7) | 14 (1.5) |
| M6, no. (%) | 2 (0.8)† | 0 (0) | 2 (1.4) | 46 (5.0) |
| M7, no. (%) | 0 (0) | 2 (1.2) | 0 (0) | 10 (1.1) |
| RAEB-t, no. (%) | 7 (2.9) | 1 (0.6) | 2 (1.4) | 37 (4.0) |
| RAEB1, no. (%) | 1 (0.4) | 0 (0) | 0 (0) | 5 (0.5) |
| RAEB2, no. (%) | 2 (0.8) | 0 (0) | 2 (1.4) | 10 (1.1) |